

Hong Kong Exchange Limited and the Exchange of Hong Kong Limited
are not responsible for the content of this announcement or for any
consequences arising from its use.

FOSUN PHARMA 复星医药

上海復星醫藥（集團）股份有限公司

(Incorporated in the People's Republic of China)
(Company No. 913100000000000000)

(Incorporated in the People's Republic of China)

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information

The board of directors (the “**董事會**”) and the supervisory committee (the “**監事會**”) of the Company and its directors, supervisors and senior management warrant that the quarterly report does not contain any false information, misleading statements or material omission and severally and jointly accept legal responsibility for the truthfulness, accuracy and completeness of the contents contained herein.

Mr. Wu Yifang, the person in charge of the Company, Ms. Yan Jia, the Chief Financial Officer, and Ms. Li Jing, the Director of the Accounting Department (Accounting Officer) warrant the truthfulness, accuracy and completeness of the financial statements contained in the quarterly report of the Group.

The financial statements for the 2022 Third Quarterly Report of the Group has not been audited.

(1) Major accounting information and financial indicators

Unit: Yuan Currency: RMB

	2022年1-9月	较上年同期增减 (%)	2021年1-9月	较上年同期增减 (%)
Operating revenue	10,270,017,624.77	1.72	31,610,071,303.19	16.87
Net profit attributable to shareholders of the listed company ^{o e 2}	907,033,448.21	-16.20	2,454,367,005.07	-31.15
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss	997,232,651.37	10.19	2,859,070,191.44	15.51
Net cash flow generated from operating activities	1,353,331,940.11	3.38	3,173,702,942.32	5.24
Basic earnings per share (RMB/share) ^{o e 2}	0.34	-19.05	0.95	-31.65
Diluted earnings per share (RMB/share) ^{o e 2}	0.34	-19.05	0.95	-31.65
Return on weighted average net asset (%)	2.18	Decrease by 0.63 percentage points	6.14	Decrease by 3.26 percentage points

	2022年12月31日	较上年同期增减 (%)	2021年12月31日	较上年同期增减 (%)
Total assets	104,329,254,170.04		93,293,790,957.96	11.83
Equity attributable to shareholders of the listed company	43,525,911,795.52		39,191,949,140.14	11.06

^{o e 1}: The “Reporting Period” refers to the three months period from the beginning of this quarter to the end of this quarter, the same below.

^{o e 2}: In the first three quarters of 2022, net profit after deducting extraordinary gain or loss attributable to shareholders of the listed company amounted to RMB2.859 billion, representing a period-on-period increase of 15.51%. For the first three quarters of 2022, the period-on-period decrease in net profit attributable to shareholders of listed company, basic earnings per share and diluted earnings per share were mainly due to the period-on-period decrease in extraordinary gains or losses resulting from losses on fair value changes: due to market fluctuations and other factors, the share price of BNTX held by the Group decreased at the end of the Reporting Period compared to the end of 2021, and the net effect of, among others, fair value losses resulting from changes in the share price of BNTX was approximately RMB1.1 billion.

(2) Extraordinary gain or loss items and amounts

Unit: Yuan Currency: RMB

	2019	2018
Gain or loss on disposal of non-current assets	241,952,331.61	807,062,468.09
Government grant included in profit or loss for the current period (excluding government grant closely related to the Company's normal operation, and entitled in fixed amounts or quantities on a continuous basis according to national standards)	14,078,593.93	54,242,711.99
Profit or loss arising from changes in the fair value of holding financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and investment income from disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except effective hedging business related to the Company's normal operations	-188,976,571.44	-844,068,109.46
Non-operating income and expenses other than those stated above	-15,359,584.25	-189,688,805.02
Other profit or loss items that fall within the meaning of extraordinary gain or loss	-44,020,277.96	-86,710,962.72
Less: Effect of income tax	-56,844,568.85	-164,053,754.94
Impact on non-controlling interests (after tax)	-41,029,126.20	18,513,265.69
Total	-90,199,203.16	-404,703,186.37

(3) Changes in the principal accounting information and financial indicators and reasons for the changes

Item	Change (%)	Reason
Net profit attributable to shareholders of listed company for the first three quarters	-31.15	In the first three quarters of 2022, net profit after deducting extraordinary gain or loss attributable to shareholders of listed company amounted to RMB2.859 billion, representing a period-on-period increase of 15.51%. For the first three quarters of

(1) Total number of holders of ordinary shares and holders of preference shares with resumed voting rights, and the shareholding status of the Top 10 shareholders

Unit: Share

Total number of holders of ordinary shares as at the end of the Reporting Period		314,459	Total number of holders of preference shares with resumed voting rights as at the end of the Reporting Period (if any)		N/A	
Shareholder Name	Type of Shareholder	Number of Shares	Percentage (%)	Number of Shares	Shareholding Status	
					Number of Shares	Percentage (%)
Fosun High Technology	Domestic non-state owned legal entity	892,008,655 ^{o e 1}	33.41	0	None	0
HKSCC NOMINEES LIMITED ^{o e 2}	Unknown	551,360,830	20.65	0	Unknown	—
HONG KONG SECURITIES CLEARING COMPANY LIMITED ^{o e 3}	Others	52,323,263	1.96	0	None	0
PERSEVERANCE ASSET MANAGEMENT L.L.P. — GAO YI LINGSHAN NO. 1 YUANWANG FUND* (高毅鄰山1號遠望基金)	Securities investment fund	47,619,047	1.78	47,619,047	None	0
CHINA SECURITIES FINANCE CORPORATION LIMITED* (中國證 金融股份有限公司)	Others	38,736,079	1.45	0	None	0
UBS AG	Qualified Foreign Institutional Investor	21,594,745	0.81	20,095,238	None	0
Qiu Mingjing (邱明靜)	Domestic natural person	17,690,000	0.66	0	None	0
BANK OF CHINA LIMITED — CHINA MERCHANTS NATIONAL SECURITIES BIOMEDICAL INDEX CLASSIFIED SECURITIES INVESTMENT FUND* (招商國證生物醫藥指數 級證 投資基金)	Securities investment fund	16,882,039	0.63	0	None	0
INDUSTRIAL AND COMMERCIAL BANK OF CHINA — SSE INDEX 50 TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND	Securities investment fund	9,181,755	0.34	0	None	0
CHINA CONSTRUCTION BANK CORPORATION — E FUND CSI 300 MEDICAL AND HEALTHCARE TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND (易方達滬深300醫藥衛生交易型開放式指數證 投資基金)	Securities investment fund	7,974,745	0.30	0	None	0

Fosun High Technology	892,008,655	RMB ordinary shares	892,008,655
HKSCC NOMINEES LIMITED ^{o e 2}	551,360,830	Overseas listed foreign shares	551,360,830
HONG KONG SECURITIES CLEARING COMPANY LIMITED ^{o e 3}	52,323,263	RMB ordinary shares	52,323,263
CHINA SECURITIES FINANCE CORPORATION LIMITED* (中國證 金融股份有限公司)	38,736,079	RMB ordinary shares	38,736,079
Qiu Mingjing (邱明靜)	17,690,000	RMB ordinary shares	17,690,000
BANK OF CHINA LIMITED — CHINA MERCHANTS NATIONAL SECURITIES BIOMEDICAL INDEX CLASSIFIED SECURITIES INVESTMENT FUND* (招商國證生物醫藥指數 級證 投資基金)	14,551,908	RMB ordinary shares	14,551,908
INDUSTRIAL AND COMMERCIAL BANK OF CHINA — SSE INDEX 50 TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND	9,181,755	RMB ordinary shares	9,181,755
CHINA CONSTRUCTION BANK CORPORATION — E FUND CSI 300 MEDICAL AND HEALTHCARE TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND* (易方達滬深300醫藥衛生交易型開放式指數證 投資基金)	7,974,745	RMB ordinary shares	7,974,745
BANK OF SHANGHAI CO., LTD. — YINHUA CSI INNOVATIVE DRUG INDUSTRY TRADING OPEN-END INDEX SECURITIES INVESTMENT FUND* (銀華中證新藥產業交易型開放式指數證 投資基金)	5,059,095	RMB ordinary shares	5,059,095
CHINA MERCHANTS BANK CO., LTD. — XINGYE INCOME ENHANCEMENT BOND SECURITIES INVESTMENT FUND* (興業收益增強青 型證 投資基金)	3,730,000	RMB ordinary shares	3,730,000
Description of the related relationship or concerted action of the above shareholders	The Company does not know whether any related relationship or concerted action exists between the abovementioned shareholders of tradable shares.		
Status description of Top 10 shareholders and Top 10 unrestricted shareholders participating in securities margin trading and refinancing business (if any)	Qiu Mingjing (邱明靜) holds 17,690,000 shares, all of which are held through securities margin trading account.		

^{o e 1}: Representing A shares only;

^{o e 2}: HKSCC NOMINEES LIMITED, i.e. Hong Kong Securities Clearing Company Nominees Limited, is holding shares on behalf of multiple clients (shares held by it at the end of the Reporting Period includes an aggregate of 77,533,500 H shares of the Company held by Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科 (集團)有限公司) (“*Shanghai Fosun High Technology (Group) Company Limited*”) and its controlling shareholder, Fosun International Limited, through it, representing approximately 2.90% of the total share capital of the Company as at the end of the Reporting Period);

^{o e 3}: HONG KONG SECURITIES CLEARING COMPANY LIMITED is the nominee holder of the RMB ordinary shares under Shanghai-Hong Kong Stock Connect.

The investors are reminded to pay attention to other significant information concerning the Company's operations during the Reporting Period

(Q) 1. 2022年前三季度经营情况

In the first three quarters of 2022, the Group adhered to the implementation of the "4IN" strategy and has kept focusing on the development of business lines of various divisions, and continued to advance its internationalization strategy.

In the first three quarters of 2022, the Group's operating revenue and net profit after deducting extraordinary gain or loss attributable to shareholders of the listed company continued to grow. In the first three quarters, the operating revenue of the Group amounted to RMB31.610 billion, representing a period-on-period increase of 16.87%; net profit attributable to shareholders of the listed company after deducting extraordinary profit or loss amounted to RMB2.859 billion, representing a period-on-period increase of 15.51%; net cash flow from operating activities amounted to RMB3.174 billion, representing a period-on-period increase of 5.24%. Due to market fluctuations and other factors, the price of shares of BNTX held by the Group as of the end of the Reporting Period declined as compared with the end of 2021, and the net effect of fair value loss due to changes in the share price of BNTX was approximately RMB1.1 billion. As a result of the loss from change in fair value of financial assets held by the Group, the Group's extraordinary profit or loss for the first three quarters was RMB-405 million, representing a period-on-period decrease of RMB1.494 billion. Due to the period-on-period decrease in extraordinary gain or loss, the Group's net profit attributable to shareholders of the listed company for the first three quarters was RMB2.454 billion, representing a period-on-period decrease of 31.15%.

In the first three quarters of 2022, the total R&D expenditure of the Group amounted to RMB3.761 billion, representing a period-on-period increase of 19.36%. In particular, the R&D expenses amounted to RMB2.849 billion, representing a period-on-period increase of RMB435 million or 18.02%.

Since July 2022, the Group's main operations and product research and development progress are as follows:

➤- ***Full commercialisation of the Azvudine jointly developed by the Company and Genuine Biotech***

In July 2022, Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) (“

lymphoma within 12 months after first-line immunochemotherapy) (r/r LBCL) of YI KAI DA was accepted in October 2022 and was included in the list of priority review products.

As of the date of this report, the application for market launch of three indications (squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC) and esophageal squamous cell carcinoma (ESCC)) of HANSIZHUANG (serplulimab Injection) that is independently developed by the Group has been accepted successively by the National Medical Products Administration of the People's Republic of China* (中華人民共和國國家藥品監督管理局). In particular, the results of phase III clinical trial of HANSIZHUANG (serplulimab Injection) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC) were published in September 2022 in the Journal of the American Medical Association (i.e. JAMA, Factors of Impact: 157.3), one of the four top medical journals in the world.

Furthermore, HAN QU YOU (trastuzumab injection), a product independently developed by the Group and licensing to Cipla Limited with its subsidiaries, was approved for market launch in Australia in July 2022. The product was approved for indications include ① HER2-positive early-stage breast cancer, ② HER2-positive locally advanced breast cancer, ③ HER2-overexpressing metastatic breast cancer, and ④ HER2-positive advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. So far, the approved indications of the product in Australia have covered all approved indications of the branded drug in that country.

In 2022, the vaccination of Comirnaty (mRNA COVID-19 Vaccine) and the process of registration of new dosage in Hong Kong, Macau and Taiwan have been continued. In particular, the vaccination of dosage for infants was approved in August 2022 for infants aged 6 months to 4 years old in Taiwan, China while the vaccination of dosage for children has been approved in May 2022. Dosage G7390062022.ihp.ppt and

into a global collaboration to co-develop Keverprazan Hydrochloride, which will be exclusively commercialized by Fosun Pharmaceutical Industrial. The collaboration scope includes all available indications of Keverprazan Hydrochloride oral drug product and common injection. In addition, in October 2022, the Company and China Resources Pharmaceutical Group Limited* (華潤醫藥控股有限公司) entered into a strategic cooperation, pursuant to which both parties will strengthen their global layout and industrial development in the relevant fields through strategic and business cooperation focusing on innovative drugs, biological drugs, medical devices and others in big health field.

▲ - **Enhanced ESG (environmental, social and governance) grading**

The Company was ranked among the top 40 in the first Fortune China ESG Influence List* (《財富》中國ESG影響 榜單) in August 2022. In October 2022, the Company's MSCI ESG rating was further upgraded from grade BBB to grade A, which outperformed other industry peers in China.

() → 1 1 1

1. In July 2022, the Company completed the non-public issuance of A shares, issuing 106,756,666 new A shares and raising a total of RMB4.484 billion. Upon the completion of the non-public issuance of A shares, the total share capital of the Company increased from 2,562,898,545 shares to 2,669,655,211 shares.
2. In July 2022, the National Association of Financial Market Institutional Investors accepted the registration of the Company's super and short-term commercial papers with a registered amount of RMB6 billion. The registered amount is valid for 2 years from 14 July 2022. The Company can issue in tranches within the effective period of the registration.
3. In August 2022, the National Association of Financial Market Institutional Investors accepted the registration of the Company's medium-term notes with a registered amount of RMB4 billion. The registered amount is valid for 2 years from 12 August 2022. The Company can issue the notes in tranches within the effective period of the registration.

Not applicable

30 e e e 2022

Unit: Yuan Currency: RMB Type of audit: Unaudited

Cash and bank balances	14,867,225,319.98	10,308,157,065.27
Financial assets held for trading	1,778,099,831.41	4,241,069,085.61
Bills receivable	22,906,765.81	16,227,279.63
Trade receivable	7,252,224,411.52	6,029,232,584.33
Receivables financing	554,156,181.44	427,883,962.35
Prepayments	1,720,614,589.13	1,738,129,227.24
Other receivables	627,106,023.29	842,558,024.99
Including: Dividends receivable	19,678,020.08	19,678,020.08
Inventories	6,772,959,245.40	5,472,315,468.74
Assets held for sale	419,577,812.77	463,704,813.34
Non-current assets due within one year	138,558,166.68	188,839,750.00
Other current assets	389,505,102.62	696,516,028.18
Total current assets	34,542,933,450.05	30,424,633,289.68
Long-term receivables	81,845,530.56	77,395,288.47
Long-term equity investments	23,190,492,783.67	22,683,713,418.51
Other equity instrument investments	17,176,545.49	29,915,556.21
Other non-current financial assets	1,798,931,480.82	1,206,488,930.44
Fixed assets	10,145,143,384.87	8,918,876,913.76
Construction in progress	3,893,035,544.64	3,617,704,520.01
Right-of-use assets	809,407,754.33	747,347,175.47
Intangible assets	12,055,501,647.58	10,276,254,397.82
Development expenditures	3,400,430,394.01	3,156,906,315.18
Goodwill	10,698,415,763.69	9,399,987,036.57
Long-term deferred expenditures	525,392,244.14	475,236,970.94
Deferred tax assets	375,480,463.13	265,589,462.47
Other non-current assets	2,795,067,183.06	2,013,741,682.43
Total non-current assets	69,786,320,719.99	62,869,157,668.28
Total assets	104,329,254,170.04	93,293,790,957.96

(Continued)
30 e e e 2022

Short-term loans	11,829,019,528.42	9,420,129,313.44
Bills payable	827,754,111.21	548,388,304.87
Trade payable	4,623,985,005.37	4,515,272,864.69
Contract liabilities	1,268,442,362.04	1,150,274,106.91
Wages payable	1,285,108,235.72	1,295,840,246.83
Tax payable	905,204,493.71	727,522,247.25
Other payables	4,720,682,046.45	4,996,429,841.33
Including: Dividends payable	33,436,354.05	28,831,507.09
Non-current liabilities due within one year	5,425,254,226.79	5,127,487,867.14
Other current liabilities	376,076,539.94	1,528,600,495.19
Total current liabilities	31,261,526,549.65	29,309,945,287.65
Long-term loans	11,706,969,842.17	6,694,183,385.90
Bonds payable	499,315,312.49	2,354,886,327.49
Lease liabilities	671,605,121.87	648,360,205.12
Long-term payables	224,922,743.84	245,793,336.10
Long-term wages payable	43,952,400.00	54,425,000.00
Deferred income	530,914,214.07	512,806,418.38
Deferred tax liabilities	3,391,285,022.56	3,129,746,176.23
Other non-current liabilities	2,772,424,772.92	1,968,080,369.57
Total non-current liabilities	19,841,389,429.92	15,608,281,218.79
Total liabilities	51,102,915,979.57	44,918,226,506.44
Share Capital	2,669,655,211.00	2,562,898,545.00
Capital reserve	16,961,552,602.67	14,029,021,356.33
Other comprehensive income	-1,023,201,091.49	-1,265,831,690.95
Surplus reserve	2,826,306,841.05	2,826,306,841.05
Retained profits	22,091,598,232.29	21,039,554,088.71
Total equity attributable to the owners (or shareholders) of the parent company	43,525,911,795.52	39,191,949,140.14
Non-controlling interests	9,700,426,394.95	9,183,615,311.38
Total owners' equity (or shareholders' equity)	53,226,338,190.47	48,375,564,451.52
Total liabilities and owners' equity (or shareholders' equity)	104,329,254,170.04	93,293,790,957.96

e o n a e o
e C o n :

C e F u n a e :

D e o o
e A o n n D e a :

June 30, 2022

Unit: Yuan Currency: RMB Type of audit: Unaudited

I. Total operating revenue	31,610,071,303.19	27,048,280,045.37
Including: Operating revenue	31,610,071,303.19	27,048,280,045.37
II. Total operating costs	29,398,980,915.03	25,425,602,296.23
Including: Operating costs	16,907,922,929.37	13,636,234,949.39
Tax and surcharges	164,764,944.45	172,834,094.24
Selling expenses	6,482,786,801.90	6,558,523,039.78
General and administrative expenses	2,617,341,150.70	2,250,761,651.93
Research and development expenses	2,848,545,845.20	2,413,787,522.55
Finance costs	377,619,243.41	393,461,038.34
Including: Interest expenses	697,287,664.37	632,128,241.84
Interest income	198,218,330.73	174,506,420.51
Plus: Other gains	247,140,432.71	178,525,743.15
Investment income (“-” indicating loss)	3,053,470,757.55	1,849,134,316.25
Including: Investment income from associates and joint ventures	1,220,658,910.22	1,321,105,089.92
Gains from changes in fair value (“-” indicating loss)	-1,930,779,093.73	1,322,786,570.87
Credit impairment losses (“-” indicating loss)	-34,904,497.28	-20,342,785.40
Asset impairment losses (“-” indicating loss)	-93,589,712.36	-246,291,983.30
Gains from disposal of assets (“-” indicating loss)	140,104,537.54	-7,272,716.06
III. Operating profit (“-” indicating loss)	3,592,532,812.59	4,699,216,894.65
Plus: Non-operating revenue	16,763,161.55	23,103,255.88
Less: Non-operating expenses	206,451,966.56	56,112,339.40
IV. Total profit (“-” indicating total loss)	3,402,844,007.58	4,666,207,811.13
Less: Income tax expenses	611,539,705.21	731,265,667.91
V. Net profit (“-” indicating net loss)	2,791,304,302.37	3,934,942,143.22
(i) Classification according to the continuity of operation		
1. Net profit from continuing operation (“-” indicating net loss)	2,791,304,302.37	3,934,942,143.22
2. Net profit from discontinued operation (“-” indicating net loss)	—	—
(ii) Classification according to ownership		
1. Net profit attributable to the shareholders of the parent company (“-” indicating net loss)	2,454,367,005.07	3,564,733,323.53
2. Profit or loss attributable to non-controlling interests (“-” indicating net loss)	336,937,297.30	370,208,819.69

(Continued)
 June 30, 2022

	2022	2021
Cash received from capital contribution	4,576,106,656.28	793,353,791.29
Including: Cash received by subsidiaries from investments of non-controlling interests	119,907,907.76	793,353,791.29
Cash received from borrowings	24,735,091,427.40	21,253,536,266.29
Other cash received relating to financing activities	543,599,653.56	275,345,953.60
Sub-total of cash inflow generated from financing activities	29,854,797,737.24	22,322,236,011.18
Cash paid for debts settlement	20,782,333,623.69	19,874,634,563.23
Cash paid for the distribution of dividends, profits or interests	2,250,716,593.12	1,847,652,871.76
Including: Dividends and profits paid by subsidiaries to non-controlling interests	137,446,317.40	116,663,427.22
Other cash paid relating to financing activities	1,878,618,427.59	1,344,638,932.39
Sub-total of cash outflow generated from financing activities	24,911,668,644.40	23,066,926,367.38
Net cash flow generated from financing activities	4,943,129,092.84	-744,690,356.20
Plus: Cash paid for purchasing goods and receiving services	319,317,772.15	-75,845,764.86
Plus: Cash paid for other operating activities	4,233,738,524.33	-390,160,202.52
Plus: Opening balance of cash and cash equivalents	6,450,650,095.59	7,324,881,260.28
Plus: Cash paid for other operating activities	10,684,388,619.92	6,934,721,057.76

Note: The items "Cash paid for purchasing goods and receiving services" and "Other cash paid relating to operating activities" for the first three quarters of 2021 (Jan-Sept) had been restated due to the adjustment of transportation costs.

Financials
 of the Company

Consolidated Financials

Financials of the Company

30 e e e 2022

Unit: Yuan Currency: RMB Type of audit: Unaudited

Cash and bank balances	2,291,315,370.69	768,036,013.63
Other receivables	5,024,486,397.71	6,643,892,558.26
Including: Dividends receivable	182,342,267.01	182,342,267.01
Assets held for sale	419,577,812.77	419,577,812.77
Non-current assets due within one year	2,944,830,000.00	2,938,030,000.00
Other current assets	694,696,057.92	373,967,911.98
Total current liabilities	11,374,905,639.09	11,143,504,296.64
Other non-current financial assets	119,972,858.05	66,942,097.48
Long-term equity investments	31,916,316,405.84	29,614,377,179.77
Fixed assets	6,959,421.57	6,875,642.89
Intangible assets	1,711,958.00	2,085,143.02
Other non-current assets	4,928,799,284.01	4,791,720,146.05
Total non-current assets	36,973,759,927.47	34,482,000,209.21
Total assets	48,348,665,566.56	45,625,504,505.85
Short-term loans	3,937,155,533.67	3,494,083,642.11
Wages payable	64,085,007.13	103,445,897.10
Tax payable	35,858,910.91	114,469,581.93
Other payables	2,528,200,014.81	3,319,990,211.62
Non-current liabilities due within one year	3,404,159,455.27	2,258,231,346.51
Other current liabilities	207,220,137.21	1,213,795,137.21
Total current liabilities	10,176,679,059.00	10,504,015,816.48
Long-term loans	3,483,200,000.00	2,802,000,000.00
Bonds payable	499,315,312.49	2,354,886,327.49
Deferred tax liabilities	1,151,018,873.79	1,151,018,873.79
Total non-current liabilities	5,133,534,186.28	6,307,905,201.28
Total liabilities	15,310,213,245.28	16,811,921,017.76

(Continued)
30 e e e 2022

Share capital	2,669,655,211.00	2,562,898,545.00
Capital reserve	18,702,293,366.09	14,363,581,643.18
Other comprehensive income	-154,718,836.55	-41,330,954.39
Surplus reserve	1,281,449,272.50	1,281,449,272.50
Retained profits	10,539,773,308.24	10,646,984,981.80
Total owners' equity (or shareholders' equity)	33,038,452,321.28	28,813,583,488.09
Total liabilities and owners' equity (or shareholders' equity)	48,348,665,566.56	45,625,504,505.85

e o n n e o

e Co n :

C e F n n e :

D e o o

e A o n n D e a :

June 30, 2022

Unit: Yuan Currency: RMB Type of audit: Unaudited

	(元)	(元)
I. Operating revenue	4,945,815.71	3,008,397.82
Less: Tax and surcharges	107,275.69	278,390.00
General and administrative expenses	145,027,230.71	118,162,462.31
Finance costs	300,817,176.40	165,520,695.01
Including: Interest expenses	362,801,318.08	397,761,921.79
Interest income	102,765,537.09	239,143,215.24
Plus: Other income	—	9,945.70
Investment income (“-” indicating loss)	1,698,506,375.22	1,889,225,507.94
Including: Investment income from associates and joint ventures	1,547,191,990.72	1,542,733,736.00
Gains from changes in fair value (“-” indicating loss)	55,308,060.53	-6,232,713.61
Asset impairment losses (“-” indicating loss)	—	-37,545,685.54
Gains from disposal of assets (“-” indicating loss)	42,141.02	56,217.25
II. Operating profit (“-” indicating loss)	1,312,850,709.68	1,564,560,122.24
Plus: Non-operating revenue	—	—
Less: Non-operating expenses	8,475,472.00	667,607.00
III. Total profit (“-” indicating total loss)	1,304,375,237.68	1,563,892,515.24
Less: Income tax expenses	9,264,049.75	—
IV. Net profit (“-” indicating net loss)	1,295,111,187.93	1,563,892,515.24
(i) Net profit from continuing operation (“-” indicating net loss)	1,295,111,187.93	1,563,892,515.24
(ii) Net profit from discontinued operation (“-” indicating net loss)	—	—
V. Other comprehensive income, net of tax	-80,245,756.42	67,527,499.18
(i) Other comprehensive income not reclassified subsequently to profit or loss	—	10,724,984.42
1. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit or loss	—	10,724,984.42
(ii) Other comprehensive income reclassified subsequently to profit or loss	-80,245,756.42	56,802,514.76
1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss	-80,245,756.42	56,802,514.76
VI. Total comprehensive income	1,214,865,431.51	1,631,420,014.42
VII. Earnings per share:		
(i) Basic earnings per share (RMB yuan/share)	N/A	N/A
(ii) Diluted earnings per share (RMB yuan/share)	N/A	N/A

Continuing operation

Company

Continuing operation

Discontinued operation

Discontinued operation

